CATIE: Learning to Live With large Comparative Trials
This article was originally published in RPM Report
Executive Summary
Pharma has come a long way in the last three years in developing tactics to respond to large, government-funded comparative clinical trials. Aggressive and well-prepared responses by the antipsychotic manufacturers to the CATIE comparison of four atypical brands to perphenazine changed what could have been a threatening study into an event for publicizing the strengths of individual brands.
You may also be interested in...
Clozapine Reaction Shows Comparative Effectiveness In Transition
A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs
Clozapine Reaction Shows Comparative Effectiveness In Transition
A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs
The FDA Roundtable Part I: The Regulators' View of Drug Development
Three top FDA officials sat down with The RPM Report at their White Oak campus to discuss the top drug regulatory issues. On the table for discussion: drug safety, comparative effectiveness and the future of drug development.